To include your compound in the COVID-19 Resource Center, submit it here.

Avrobio falls on data for Fabry gene therapy

Avrobio Inc. (NASDAQ:AVRO) said peripheral blood average vector copy number (VCN) declined over time in four Fabry disease patients who received a single dose of gene therapy AVR-RD-01 in either a Phase I or Phase II trial.

The news sent the company’s shares tumbling

Read the full 440 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers